Marianne De Backer sold $474k of VIR
Chief Executive Officer at Vir Biotechnology, Inc.. 79,712 shares at an average of $5.95, traded Apr 3, 2025, filed Apr 4, 2025.
Score components
- +25RoleCEO
- +17Trade size$474k at market
- 0Share of holdings soldSold 9.4% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-016800, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 3, 2025 | SOpen-market sale Common Stock10b5-1 | -79,712 | $5.95 | $474k | 769,505 | Apr 4, 2025 |
Related signals
Other insiders at Vir Biotechnology, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 5Weak | Vir Biotechnology, Inc. | Vicki L Sato director | $110k 22,000 shares | -2% | |
| 5Weak | Vir Biotechnology, Inc. | Vicki L Sato director | $110k 22,000 shares | -2% | |
| 10Weak | Vir Biotechnology, Inc. | Mark Eisner EVP and Chief Medical Officer | $57k 10,382 shares | -9% | |
| 13Weak | Vir Biotechnology, Inc. | Vicki L Sato director | $112k 22,000 shares | -2% | |
| 0Weak | Vir Biotechnology, Inc. | Janet Napolitano director | $16k 3,200 shares | -16% | |
| 24Weak | Vir Biotechnology, Inc. | Marianne De Backer Chief Executive Officer | $152k 16,122 shares | -2% | |
| 19Weak | Vir Biotechnology, Inc. | Ann M. Hanly EVP & Chief Technology Officer | $134k 14,168 shares | -11% | |
| 15Weak | VIRsell Vir Biotechnology, Inc. | Vanina de Verneuil EVP and General Counsel | $625 76 shares | -0% | |
| 1Weak | Vir Biotechnology, Inc. | Vanina de Verneuil EVP and General Counsel | $44k 4,397 shares | -7% | |
| 0Weak | Vir Biotechnology, Inc. | Vanina de Verneuil EVP and General Counsel | $32k 3,750 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.